Agios Pharmaceuticals Inc (AGIO) reported quarterly earnings results on Thursday, May-5-2016. The company said it had a profit of $-0.64 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.29. Analysts had a consensus of $-0.93. The company posted revenue of $31.28 million in the period, compared to analysts expectations of $25.66 million. The company’s revenue was down -8.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.13 EPS.
Many Wall Street Analysts have commented on Agios Pharmaceuticals Inc. Sun Trust Rbsn Humphrey Initiated Agios Pharmaceuticals Inc on Mar 30, 2016 to “Buy”, Price Target of the shares are set at $57.
Agios Pharmaceuticals Inc closed down -2.36 points or -5.07% at $44.16 with 7,06,378 shares getting traded on Wednesday. Post opening the session at $46.42, the shares hit an intraday low of $43.91 and an intraday high of $46.57 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Apr 27, 2016, Lewis Clayton Jr. Cantley (director) sold 2,504 shares at $53.44 per share price. According to the SEC, on Jan 5, 2016, Scott Biller (Chief Scientific Officer) sold 5,500 shares at $65.27 per share price. On Dec 17, 2015, John Duncan Higgons (Chief Operating Officer) sold 20,000 shares at $50.09 per share price, according to the Form-4 filing with the securities and exchange commission.
Agios Pharmaceuticals Inc. (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells. Its products include AG-221 AG-120 and AG-348. Its lead product AG-348 in the RGD program is an orally available small molecule that targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. AG-221 is potent inhibitor of the mutated IDH2 protein being developed for the treatment hematological malignancies and advanced solid tumors. AG-120 is an orally available selective potent inhibitor of the mutated IDH1 protein being developed for the treatment hematological malignancies and advanced solid tumors.